Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial

Fineline Cube Dec 7, 2024

Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...

Company Deals

AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics

Fineline Cube Dec 7, 2024

US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with...

Company Drug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

Fineline Cube Dec 7, 2024

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...

Policy / Regulatory

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Dec 7, 2024

The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...

Company Drug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Fineline Cube Dec 7, 2024

Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...

Company Drug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment

Fineline Cube Dec 6, 2024

The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...

Company Deals

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine

Fineline Cube Dec 6, 2024

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...

Company Deals

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets

Fineline Cube Dec 6, 2024

GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics,...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Fineline Cube Dec 6, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy...

Company Drug

Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment

Fineline Cube Dec 6, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration...

Company Drug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Fineline Cube Dec 6, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...

Company Deals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion

Fineline Cube Dec 6, 2024

China-based ophthalmic medical device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050), has announced plans...

Company Deals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Fineline Cube Dec 6, 2024

US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...

Company Deals Drug

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

Fineline Cube Dec 6, 2024

US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...

Company Drug

AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer

Fineline Cube Dec 6, 2024

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...

Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Fineline Cube Dec 6, 2024

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its...

Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Fineline Cube Dec 6, 2024

US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance...

Company Drug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

Fineline Cube Dec 6, 2024

US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...

Company Drug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Fineline Cube Dec 6, 2024

China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...

Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Fineline Cube Dec 5, 2024

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the...

Posts pagination

1 … 195 196 197 … 609

Recent updates

  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.